BACKGROUND: several reports suggest that the efficacy of adjuvant chemotherapy on survival diminishes over time for colon cancer; however, precise timing of its loss of benefit has not been established.
C olorectal cancer is the third leading cause of cancer-related deaths in the united states, with an estimated 130,000 new cases to be diagnosed in 2015. 1 although surgery remains the cornerstone of curative treatment for nondisseminated colon cancers, adjuvant chemotherapy (aC) has consistently demonstrated a survival benefit of up to 30% in randomized trials. 2, 3 hence, the national Comprehensive Cancer network currently recommends 5-flurouracil-based aC after curative resection for patients with high-risk stage ii and stage iii colon cancers. [4] [5] [6] Despite its proven efficacy, there is relatively little guidance on the delivery of aC, particularly regarding its optimal initiation time after surgery. there is a widespread clinical assumption that aC should be started as soon as possible, based on the design of clinical trials with aC commencing within 6 to 10 weeks after surgery. additionally, several studies suggest an increased risk of recurrence and death in patients who experience delay. 7-10 this practice was supported by a 2012 landmark meta-analysis by Biagi et al 11 that demonstrated a 14% decrease in overall survival associated with delay. given this evidence, some have advocated using the timeliness of aC as a quality-ofcare measure in the treatment of colon cancer. 12 although the general negative impact of delaying aC is evident, a specific optimal time for the initiation of aC is not well defined. in closer examination of data presented by Biagi et al, 11 the risks of mortality associated with increasing time to aC in clinical trials were not constant or linear. furthermore, conclusions drawn from previous studies were based on indirect analysis of the time to aC. so far, there has been no randomized, direct data on the most ideal timing. therefore, we sought to examine the association between time to initiating aC and survival in colon cancers by using a generalizable national-level data set, with the hypothesis that an optimal threshold for the initiation of aC may be determined.
MATERIALS AND METHODS

Study Design
We queried the national Cancer Data Base (nCDB), which collects information on approximately 70% of all newly diagnosed cancer cases in the united states and Puerto Rico from more than 1500 cancer centers. The NCDB 1998 to 2011 Participant Use File for colon cancer was used for the analysis.
adults from the 2006 nCDB who received aC following resection of pathologic stage ii and iii colon adenocarcinomas were selected based on International Classification of Diseases for Oncology, Third Edition histology codes (8140, 8141, 8143, 8144, 8145, 8147, 8150, 8210, 8211, 8260, 8261, 8262, 8263, 8310, 8320, 8323, 8380, 8401, 8410, 8440, 8460, 8470, 8490, 8500, 8503, 8510) . the year 2006 was selected because of the availability of data on long-term survival and the sequence of chemotherapy administered. time to aC was determined from the difference between days to initiation of chemotherapy and days to definitive surgery. Patients with more than 1 primary malignancy, missing chemotherapy timing data, or those who died within 30 days after surgery were excluded. finally, to control the influence of outliers, cases within the top and bottom 5% of time to aC were excluded, resulting in the final distribution as shown in figure 1 . the Duke university institutional Review Board reviewed and granted exempt status for this retrospective study.
Outcomes
the primary outcome of this study was overall survival, with the aim to determine a threshold of time to aC beyond which survival was compromised. secondary outcomes include predictors associated with delay in initiating aC. Statistical Analysis to model the relationship between time to aC and survival, we developed a multivariable Cox proportional hazard model with restricted cubic splines (RCs). RCs is a piecewise polynomial function that can flexibly examine a relationship between a predictor and an outcome without assuming any relationship a priori. 13 RCs is a more accurate method to model the complex nonlinear relationship between time to aC and overall survival, while adjusting for age, sex, race, insurance status, Charlson/ Deyo comorbidity index, pathologic stage, and extent of surgery. additionally, visualization of the model output allows for an objective determination of a threshold. a bootstrap simulation that incorporated a monte Carlo markov Chain procedure was conducted to estimate and confirm the point that corresponded to the maximum change from this range of timing to therapy. 14 We determined that 3 knots at the 5th, 50th, and 90th percentile were appropriate for the RCs model based on the lowest akaike information Criterion, as previously described. 15 the model-derived threshold was then used to dichotomize the initial study cohort into "early" and "late" groups, defined as patients who received aC before and after the threshold. Comparisons were made between these groups by using the Kruskal-Wallis test for continuous variables and the Pearson χ 2 test for categorical variables. Overall survival was estimated by using the Kaplan-Meier method. multivariable logistic regression models were created to analyze factors independently associated with delay in initiating aC; a backward variable elimination method was used to produce the most parsimonious and fit model based on the lowest akaike information Criterion. to account for the effect of complications on the timeliness of adjuvant therapy, a subset analysis was performed excluding patients who were readmitted or had postoperative hospital stays greater than 7 days. model diagnostics were assessed. a p value of less than 0.05 was considered statistically significant. statistical analysis was performed using sas software version 9.4 (sas institute inc., Cary, nC).
RESULTS
in total, 7794 patients met the study criteria: 1893 (24%) with pathologic stage ii and 5901 (76%) with stage iii colon cancers. the baseline characteristics of our study cohort are shown in table 1. median time to initiating aC after surgery was 44 days (interquartile range, 34-56 days) and median follow-up was 61 months (interquartile range, 37-70 months). graphical visualization of the multivariable-adjusted Cox hazard model using RCs demonstrated a critical threshold at 44 days after surgery ( fig. 2 ). Before the model-derived threshold of 44 days, there was no association between time and overall survival (p = 0.11). however, after the threshold of 44 days, increasing time to adjuvant therapy was associated with an increase in the hazard of mortality (hR, 1.14; p = 0.002). furthermore, among the subset of patients who received aC after 44 days, each additional week of delay conferred worse survival (hR, 1.07; p < 0.001) (table 2). among the subset of patients without readmission or prolonged hospital stay (n = 2181), the risk of delay was not qualitatively different from the overall cohort (hR, 1.06; p = 0.001) (table 2) .
Based on this threshold, our initial study cohort was stratified into 2 groups: early (52%, ≤44 days) and late (48%, >44 days). Compared with the early group, patients in the late group were more likely to be older (63 vs 62 years old, p < 0.001), of black race (15% vs 11%, p < 0.001), uninsured (5% vs 3%, p < 0.001), and treated at an academic institution (28% vs 20%, p < 0.001). they also had a higher proportion of Charlson comorbidity scores greater than 1 (6% vs 5%, p = 0.035), tumors greater than 4.9 cm (46% vs 42%, p = 0.003), and stage ii disease (29% vs 20%, p < 0.001) (table 3). although both groups had similar extent of surgery (p = 0.64), similar resection margin positivity (p = 0.83), and clinically insignificant difference in hospital length of stay (6 vs 6 days, p < 0.001), patients in the late group had higher rates of unplanned readmissions (5% vs 3%, p < 0.001). in the long term, overall survival was superior among patients who received therapy in the early group (73% vs 65% at 5 years, p < 0.001) ( fig. 3 ).
following multivariable adjustment, independent predictors of delay include increasing age by decade (oR, 1.11; 95% Ci, 1.06-1.16; p < 0.001), black race (oR, 1.34; 95% Ci, 1.16-1.55; p < 0.001), Charlson comorbidity score of 2 or more (oR, 1.25; 95% Ci, 1.01-1.54; p = 0.04), treatment at an academic hospital (oR, 1.78; 95% Ci, 1.52-2.09; p < 0.001), and unplanned readmissions (oR, 1.51; 95% Ci, 1.19-1.91; p = 0.001). Patients with government (oR, 0.57; 95% Ci, 0.44-0.74; p < 0.001) or private insurance (oR, 0.52; 95% C, 0.40-0.66; p < 0.001) and stage iii disease (oR, 0.61; 95% Ci, 0.55-0.68; p < 0.001) had a higher likelihood of initiating aC before 44 days ( fig. 4 ).
DISCUSSION
in this study, we objectively determined that delaying aC beyond 44 days after surgery is associated with inferior survival, and that further delay is linked to additional risk of death. older, black, and uninsured patients were more likely to experience a delay beyond 44 days, implying that socioeconomic barriers remain significant in preventing patients from receiving optimal treatment. additionally, experiencing an unplanned readmission after surgery is related to delay, suggesting that developing a surgical complication is one of the main deterrents to obtaining timely aC. interestingly, treatment at an academic hospital is also associated with higher likelihood of delay. a previous study by Bilimoria et al 16 examining wait times for cancer surgery have corroborated this finding, and attributed the cause of delay to the higher caseloads seen at regionalized, academic centers. While academic hospital status in our data set does not equate a national Cancer institute certification, there is significant overlap between both designations in the united states. our findings confirm and help expand upon the work of other groups that have previously examined the association between time to aC and survival. in the aforementioned study by Biagi et al, 11 meta-analysis of 10 colorectal chemotherapy trials showed that each 4-week increase in time to aC is associated with a significant decrease in overall (hR, 1.14) and disease-free survival (hR, 1.14). similarly, Des guetz et al, 17 aggregating data from 14 randomized colorectal cancer chemotherapy trials, found that greater than 8 weeks delay is associated with worse overall survival (hR, 1.20). these meta-analyses are corroborated by several other small reports that arrive at the same general conclusion. [18] [19] [20] although these important studies established the clinical effect of delay in aC on long-term outcomes, both meta-analyses included patients with colon and rectal cancer, and thus are subject to confounding from a nonuniform study population. furthermore, the hazard ratios associated with increasing time to aC in clinical trials were not constant or linear. 11 Before 6 to 10 weeks, hazard ratios from most of the studies cited demonstrate no increased risk, but then rise sharply afterward. as a result, using a single hazard ratio to describe the complex relationship between time and survival may be inaccurate -a limitation of the linearity assumption of the traditional Cox proportional hazard model. our study supports the conclusions from these groups that delay is associated with inferior survival and improves upon the accuracy of optimal timing by objectively determining a threshold of 44 days.
there are several proposed mechanisms relating to timing of aC to survival. first, 10% to 20% of patients who undergo surgery for advanced colon cancer ultimately develop recurrence, suggesting that surgeons perform "curative" resections in the setting of occult metastatic disease. 21 this also implies that there is a window during which disease burden is minimal postoperatively and theoretically most vulnerable to systemic therapies. a prolonged interval between surgery and aC can therefore lead to the proliferation of micrometastases that otherwise may be susceptible to treatment. 22 moreover, the trauma of a major operation has been shown to be immunosuppressive. 23, 24 Consequently, any unresected, subclinical disease at the time surgery is given a favorable condition for increased growth in the postoperative period, and thus delay in the delivery of aC contributes significantly to inferior survival in the long term.
there are several limitations to our analysis. first, the exact regimen of chemotherapeutics is unknown because of the limitation of our data set, and therefore survival differences may exist depending on the type of chemotherapy given. however, excluding patients in clinical trials, we assume that during this time period, most patients were given a 5-flurouracil-based regimen that has similar effects on survival. 25 even in the setting of modern oxaliplatin-based therapies, overall survival only improved slightly from 76% to 78%, which should not significantly affect our analysis. 7 second, we are unable to extract specific reasons for delay of aC, because differences in patient, physician, or social factors may have significant implications on proposals for intervention. however, we did evaluate surrogates such as patient demographics and readmission rates to circumvent this issue. although surgical complications may be one of the many causes of delay, the readmission rate of 5% suggests that it was not the only driver for delay. indeed, Wasserman et al 26 published a multi-institutional study exploring predictors of delay in the delivery of aC and found that postoperative complications (oR, 2.4) and oncologist-or patient-initiated delay (oR, 3.5) were the strongest predictors of delay. this finding suggests that potential interventions or quality improvement efforts can be conducted, focusing on educating oncologists and patients in the importance of timely treatment. moreover, the use of laparoscopy was not captured in our available data set, but may decrease time to adjuvant therapy as shown in a recent analysis by Zheng et al. 27 finally, be- cause our study is retrospective in nature, there may be selection bias between those who received aC early and late. this concern was attenuated by our multivariable statistical adjustment, but inherent uncontrolled differences can still be present. nonetheless, because it may not be feasible or ethical to design a prospective study to test for the optimal timing in delivery of aC, this large study with variability in timing of the initiation of aC provides a unique opportunity to directly examine the optimal timing of aC initiation and its association with survival in a multivariable fashion. our study has a number of significant implications in the delivery of adjuvant therapy for colon cancer. first, starting aC as soon as possible (before 6 weeks) may not be necessary, and it may be better to fully optimize a patient to increase the probability of completing adjuvant therapy. this finding affirms clinical intuition that a well-recovered surgical patient experiences the best outcomes. second, because delay in initiating aC has repeatedly displayed associations with poor survival, it is important to address the reasons causing delay, which may be affecting as many as 19% of patients. 9 finally, because our analysis objectively arrived at the threshold without arbitrarily defining a cutoff, it may be used to establish an impartial quality metric in the delivery of aC for colon cancer.
CONCLUSIONS
We found that the optimal timing for delivery of aC in colon cancer is within approximately 6 weeks after surgery. Delayed administration of indicated therapy is associated with inferior survival. future quality improvement measures should be aimed at addressing socioeconomic barriers and avoiding surgical complications to achieve timely delivery of aC. 
